KCG
AIM

Knight Capital Group’s AIM ImmunoTech AIM Stock Holding History

Knight Capital Group’s Portfolio AIM Stock Details AIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q2 		$14K Buy
+1
New +$11.9K ﹤0.01% 3205

Other funds holding AIM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GC
Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return

Knight Capital Group's AIM Position: Q2 2013 in Review

Knight Capital Group opened a new position in AIM ImmunoTech (AIM) in Q2 2013: 1 share worth $14K. The stake represents ﹤0.01% of the portfolio and ranks #3205 among its holdings.

13 funds tracked by Wall St. Rank hold AIM as of Q2 2013.

  • Knight Capital Group held 1 share of AIM ImmunoTech worth $14K as of Q2 2013.
  • AIM ImmunoTech was a new Knight Capital Group position in Q2 2013.
  • AIM ImmunoTech made up ﹤0.01% of Knight Capital Group's portfolio in Q2 2013, its #3205 holding.
  • 13 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q2 2013.

Based on Knight Capital Group's 13F filing for Q2 2013, filed 8 Aug 2013.